Want to see ACRV full AI Analyst Report?
Top Page
Acrivon Therapeutics, Inc.
(NASDAQ:ACRV)
Select Model
Select Model
Rating:48Neutral
Price Target:
$2.00
▲(25.00% Upside)
Action:Reiterated
Date:08/18/26
The score is driven primarily by weak financial performance (no revenue, large losses, and persistent cash burn), partially mitigated by low leverage and positive equity. Technicals are supportive in the short term (price above key moving averages and positive MACD) but are tempered by overbought signals (high RSI/Stoch). Corporate actions add potential dilution risk via an expanded equity plan, while valuation metrics are constrained by negative earnings and no dividend data.
Positive Factors
Precision oncology platform
The proprietary AP3 platform may improve patient selection and clinical development efficiency by linking treatment candidates to responsive subgroups, creating a differentiated foundation for multiple oncology programs.
Negative Factors
No commercial revenue
A pre-revenue model leaves the company dependent on financing and successful clinical development rather than recurring commercial cash inflows, while persistent losses limit operating leverage and increase execution risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Precision oncology platform
The proprietary AP3 platform may improve patient selection and clinical development efficiency by linking treatment candidates to responsive subgroups, creating a differentiated foundation for multiple oncology programs.
Read all positive factors
Acrivon Therapeutics, Inc. (ACRV) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$83.56M
Dividend YieldN/A
Average Volume (3M)421.23K
Price to Earnings (P/E)―
Beta (1Y)1.88
Revenue GrowthN/A
EPS Growth16.04%
CountryUS
Employees75
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.88
Shares Outstanding42,853,363
10 Day Avg. Volume442,643
30 Day Avg. Volume421,228
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)0.82
Price to Sales (P/S)0.00
P/FCF Ratio-1.42
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$10.50Price Target Upside556.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-2.07
Revenue Forecast (FY)$1.50M
Acrivon Therapeutics, Inc. Business Overview & Revenue Model
Company Description
Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific med...
How the Company Makes Money
null...
Acrivon Therapeutics, Inc. Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
64
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 528.00K | -1.36M | -1.01M | -536.00K | 0.00 | 0.00 |
| EBITDA | -78.94M | -76.55M | -79.55M | -59.85M | -30.80M | -16.21M |
| Net Income | -74.22M | -77.91M | -80.56M | -60.39M | -31.17M | -16.24M |
Balance Sheet | ||||||
| Total Assets | 99.09M | 129.72M | 196.59M | 138.26M | 181.23M | 106.59M |
| Cash, Cash Equivalents and Short-Term Investments | 89.96M | 118.58M | 179.48M | 127.46M | 127.75M | 99.60M |
| Total Debt | 2.12M | 2.71M | 3.65M | 4.64M | 4.96M | 5.63M |
| Total Liabilities | 12.43M | 17.20M | 19.80M | 17.07M | 10.75M | 130.40M |
| Stockholders Equity | 86.67M | 112.52M | 176.79M | 121.19M | 170.47M | -23.81M |
Cash Flow | ||||||
| Free Cash Flow | -64.14M | -65.33M | -68.44M | -43.93M | -32.28M | -14.22M |
| Operating Cash Flow | -62.92M | -63.66M | -65.67M | -42.64M | -30.12M | -13.98M |
| Investing Cash Flow | 55.51M | 66.10M | -51.77M | 50.72M | -141.68M | -238.00K |
| Financing Cash Flow | 6.93M | -749.00K | 121.03M | -1.55M | 101.71M | 112.22M |
Acrivon Therapeutics, Inc. Technical Analysis
Positive
1.60
Price Trends
1.68
Positive
1.70
Positive
1.85
Positive
Market Momentum
0.05
Negative
70.60
Negative
87.49
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ACRV, the sentiment is Positive. The current price of 1.6 is below the 20-day moving average (MA) of 1.67, below the 50-day MA of 1.68, and below the 200-day MA of 1.85, indicating a bullish trend. The MACD of 0.05 indicates Negative momentum. The RSI at 70.60 is Negative, neither overbought nor oversold. The STOCH value of 87.49 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ACRV.
Acrivon Therapeutics, Inc. Risk Analysis
Acrivon Therapeutics, Inc. disclosed 82 risk factors in its most recent earnings report. Acrivon Therapeutics, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Acrivon Therapeutics, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
ACRV
Acrivon Therapeutics, Inc.
2.05
0.66
47.48%
MNOV
Medicinova
1.32
0.01
0.76%
ALGS
Aligos Therapeutics
6.58
-2.19
-25.03%
GNTA
Genenta Science SpA Sponsored ADR
1.26
-2.32
-64.80%
IMMX
Immix Biopharma
11.34
9.04
393.04%
CAMP
CAMP4 Therapeutics Corporation
5.00
3.14
168.82%
Acrivon Therapeutics, Inc. Corporate Events
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Acrivon Shareholders Approve Expanded Equity Plan and Directors
Positive
Jun 17, 2026
On June 17, 2026, Acrivon Therapeutics held its 2026 annual meeting of stockholders, where investors approved an amended and restated 2022 Equity Incentive Plan that expands the share pool to 8,606,723 shares, including an additional 3,000,000 sha...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.